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PALB2 has taken its place with bona fide breast cancer susceptibility genes. It is now well established that women
who carry loss-of-function mutations in the PALB2 gene are at similarly elevated breast cancer risks to those who
carry mutations in BRCA2. Information about PALB2 is now being used in breast cancer clinical genetics practice and
is routinely included in breast cancer predisposition gene panel tests. Tens of thousands of women worldwide have
now had genetic tests for PALB2 mutations in the context of breast cancer susceptibility. However, prospective data
related to the clinical outcomes of PALB2 mutation carriers is lacking and very little information (beyond mutation
penetrance) is available to guide current clinical management for carriers (affected and unaffected by cancer). In
addition, clinical classification of the vast array of non-loss-of-function genetic variants identified in PALB2 is in its
infancy. These are key areas of current research efforts and are important foundations on which to move information
about PALB2 into the precision public health arena.
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For the last two decades, women have been offered genetic
testing of BRCA1 and BRCA2 in various clinical contexts.
The vast majority of these women are seeking an explan-
ation for a personal or family history of breast and/or ovar-
ian cancer, and an accurate means of risk assessment, to
facilitate risk management across the family. Indeed clinical
criteria used to determine eligibility for BRCA1 and BRCA2
testing in many settings have been founded on the number
of affected relatives and their age at diagnosis and then
developed over time with increased evidence and local
practice issues. Of those women who undergo testing, up
to 20 % are found to carry a clinically actionable mutation
in BRCA1 or BRCA2. Until very recently additional genetic
testing was not possible unless other clinical indicators
were present (such as Li-Fraumeni syndrome that might
indicate genetic testing of TP53). Women and their families
who received uninformative genetic test results for BRCA1
and BRCA2 were clinically managed solely on the basis of
their personal and family history. This limited the use of
invasive strategies such as risk reduction surgery.* Correspondence: msouthey@unimelb.edu.au
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(http://creativecommons.org/publicdomain/zeContinued research and a recent revolution in genetic
technology that can be applied to this research has identi-
fied a number of additional breast cancer predisposition
genes and reported a large number of additional candidate
breast cancer predisposition genes that are yet to be vali-
dated. This same technology has also transitioned into
molecular diagnostic laboratories and has enabled a shift
from high cost single gene genetic tests to lower cost
multi-gene panel tests. The uptake of gene panel tests has
been rapid and included a volume of successful direct-to-
the-public marketing. In some areas of clinical genetics,
panel testing is now the standard of care [1]. With some
important caveats and considerations discussed in this re-
view, current data suggests that gene panel testing offers
breast cancer clinical genetics practice increased oppor-
tunity to identify “actionable” genetic variants in a greater
proportion of women [2–4].
However, few of the large number of genes included in
many gene panel tests are bona fide breast cancer predis-
position genes and the vast majority of genetic variation
identified by these gene panel tests cannot be interpreted
in terms of breast or ovarian cancer risk. This is currently
a controversial area of breast cancer research and clinical
genetics practice, and is discussed in detail elsewhere [5].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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number of bona fide breast cancer susceptibility genes.
It is now well established that women who carry muta-
tions in the PALB2 gene are at similar breast cancer
risks as those who carry mutations in BRCA2 [6, 7])
making many rethink the appropriateness of the initial
“moderate or intermediate risk gene” label [8]. PALB2
now plays a legitimate role in breast cancer clinical gen-
etics practice and takes a valid place on breast cancer
predisposition gene panel tests. Internationally, tens of
thousands of women, including those who have gone
direct to the test provider, have had genetic tests for
PALB2 mutations in the context of breast cancer suscep-
tibility. Today, many nations have (or are preparing) best
practice guidelines that include recommendations for
PALB2 genetic testing and risk management [5, 9].
Currently, prospective data related to the clinical out-
comes of PALB2 mutation carriers is lacking and very
little information (beyond mutation penetrance) is avail-
able to guide clinical management for carriers (affected
and unaffected by breast cancer). Over the last two de-
cades, evidence has slowly been accumulated to support
recommendations around risk management and targeted
treatment regimes for BRCA1 and BRCA2 mutation car-
riers. Very little of this evidence currently exists for
PALB2 mutation carriers.
Accumulating this evidence is challenging due to the
very low frequency of women with PALB2 mutations, even
in affected women with a strong family history of breast
and ovarian cancer. However, with new technology and
international coordination there is promise that further
evidence could be gathered for PALB2 mutation carriers
that will improve their clinical care within a few years.
In addition, risk estimates for PALB2 mutations have
been based on collections of loss-of-function mutations.
Clinical classification of the vast array of non-loss-of-
function genetic variants identified in PALB2 is in its
infancy. Informed by prior research in this area involving
unclassified genetic variants in BRCA1 and BRCA2, inter-
national initiatives are moving quickly to identify the best
approaches to assess PALB2 genetic variants on a variant-
by-variant basis, to enable personalized use in clinical
genetics practice.
PALB2 has made it over the first hurdle and is now in-
cluded in the breast cancer clinical genetics arena but to
extend current utility and have an impact on improving
the clinical outcomes for carriers of PALB2 mutations
and incorporate use of this genetic information into pre-
cision public health initiatives, additional data is still ur-
gently required.
PALB2: A bona fide breast cancer susceptibility gene
Mutations in PALB2 make a small contribution to herit-
able breast cancer susceptibility in most populations.Germline PALB2 mutations and carrier frequencies have
been reviewed elsewhere [10]. Briefly, protein truncating
mutations in PALB2 are distributed throughout the cod-
ing region [6, 10] yet four PALB2 mutations are of note in
terms of multiple observations: PALB2 c.509_510delGA
(p.Arg170fs*14) in Poland [11], PALB2 c.2323C > T
(p.Gln775*) in French Canadians [12], PALB2 c.1592delT
(p.531 fs*30) in Finland [13] and PALB2 c.3113G > A
identified in affected women in the UK, USA and
Australia [8, 14–17]. Reports from a variety of popula-
tions consistently estimate that PALB2 mutations are
associated with increased risk for breast cancer (e.g.,
OR 3.94, 95 % CI, 1.5–12.1) [13].
As few studies have been conducted within unselected
breast cancer cases, estimation of the age-specific cumu-
lative risk (penetrance) of breast cancer associated with
PALB2 mutations has been limited. The family histories
of the case carriers, unselected for age or family history,
reported in Northern Finland [13], were used to estimate
PALB2 c.1592delT to be associated with a 40 % (95 %
CI, 17 %–77 %) risk of breast cancer to the age of
70 years [18]. Similarly, an Australian population-based
case–control-family study of breast cancer estimated the
cumulative risk for PALB2 c.3113G > A to be 91 % (95 %
CI, 44–100 %) to the age of 70 years [17].
To consider penetrance of a larger number of PALB2
genetic variants and a larger number of families, the
PALB2 interest group [19] embarked on a collaborative
effort that collected data from 362 members of 154 fam-
ilies who had deleterious truncating, splice, or deletion
mutations in PALB2 [6]. The estimated average cumula-
tive risk of breast cancer risk ranged from 33 % (95 %
CI, 25–44 %) for a female carrier without affected rela-
tives to 58 % (95 % CI, 50–66 %) for a female carrier
with two first-degree relatives who had breast cancer di-
agnosed by 50 years of age. Supported by other similar
observations [20], some recommend that both family
history and PALB2 genotype should be considered to-
gether for clinical breast cancer risk management.
Thus, all published estimates of penetrance of PALB2
mutations are comparable to the breast cancer risk asso-
ciated with BRCA2 mutations: 45 % (95 % CI, 31–56 %)
[7]. PALB2 is now regarded as a bona fide breast cancer
predisposition gene and is justifiably included on current
breast cancer gene testing panels with the above evidence.
Evidence-based translation into breast cancer
clinical genetics practice
An overview of the pathway to translation of new gen-
etic information related to breast cancer clinical genetics
practice is shown in Fig. 1. This figure represents women
diagnosed with breast cancer under the age of 40 years
with a strong family history of breast and or ovarian
cancer (two or more effected first or second degree
Fig. 1 PALB2: evidence-based translation into practice. Based on the Australian Breast Cancer Family Registry and the Australian context
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have been identified in approximately 25 % of these
women. The risk associated with carrying these mutations
and the clinical outcomes for these women (collectively)
have been well characterised and this evidence is used to
inform the clinical management of these women and their
families [21]. Loss-of-function PALB2 mutations are iden-
tified in approximately 2 % of these women [17]. Breast
cancer risk associated with carrying a PALB2 loss-of-
function mutations is now established but research is
urgently needed to extend this knowledge to an under-
standing of clinical outcomes for carriers. Rare muta-
tions in genes associated with genetic syndromes such
as Li-Fraumeni (TP53), Cowden syndrome (PTEN) and
hereditary diffuse gastric cancer (CDH1) are also present in
this group of women at very low frequency. Specific evi-
dence related to clinical outcomes for breast cancer in
these contexts is lacking. Additional breast cancer suscepti-
bility genes including ATM and CHEK2 also require pro-
spective data to provide the evidence-base for clinical
decision making around risk management/reduction andtreatment options. Several other genes have been identified
as candidate breast cancer predisposition genes that re-
quire further validation such as FANCM [22] and RECQL
[23]. The remaining early-onset breast cancer cases with a
strong family history remain the subject of research trying
to identify the “missing heritability” of breast cancer via
numerous initiatives including COMPLEXO [24].
PALB2 mutations and risk of other cancer types
As PALB2 functions together with BRCA1 and BRCA2, in
the same DNA-damage response pathway, it has been
thought plausible that PALB2 mutations, similar to BRCA1
and BRCA2 mutations, could predispose to other cancer
types. The rarity of mutations in PALB2 and the rarity of
some of the other cancers likely to be involved (pancreatic,
male breast cancer, ovarian cancer, prostate cancer) make
the estimation of the risk (if any) extremely challenging.
Data in this area continues to come from small (yet
important) studies and case reports that accumulatively
may assist this interpretation ([25] and many others). By
pooling international resources, the PALB2 Interest Group
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male breast cancer for PALB2 mutation carriers was
2.31 (95 % CI, 0.77–6.97; P = 0.18) and 8.30 (95 % CI,
0.77–88.56; P = 0.08) respectively [6].
PALB2 germline mutations are rare in cases of pancre-
atic cancer [26–32]. A recent report describing the mu-
tational landscape of pancreatic cancers has illustrated
the potentially important role for paralleling somatic and
germline mutation testing to enable the identification
not just of the rare germline PALB2 mutation carriers
but also the mutation signature of DNA damage repair
deficiency in pancreatic cancers that could benefit from
platinum therapies [33].
Some substantial opportunities to assess risk for other
cancers have come from application of targeted sequencing
projects and gene panel testing. In the context of risk for
ovarian cancer, Ramus et al. have reported sequencing re-
sults for PALB2 for 3,236 women affected with epithelial
ovarian cancer and 3,431 unaffected women. Nine muta-
tion carriers were identified in the affected women and
three in the unaffected women (P = 0.08). Interestingly they
also identified seven carriers in 2,000 unaffected women
with a family history of breast or ovarian cancer (all women
had at least 10 % lifetime risk) (P = 0.045 when compared
to the controls above) [34]. Norquist et al. have reported
findings from a targeted capture and massively parallel se-
quencing assay that included the identification of 12 PALB2
mutation carriers in a group of 1,915 women with ovarian
cancer unselected for family history (P = <0.001 when com-
pared to data from the Exome Sequencing Project and the
Exome Aggregation Consortium) [35]. Two protein trun-
cating mutations in PALB2 (c.1592delT, p.Leu531Cysfs and
c.3113G >A, p.Trp1038*) were included on the iCOGS and
genotyped in 16,287 ovarian cancer cases and 23,491
controls. No evidence for association with ovarian cancer
risk was observed (OR 2.50, 95 % CI, 0.21–29.1), p = 0.45
and OR 1.34, 95 % CI, 0.36–4.97), p = 0.66 respectively)
(Southey MC, Goldgar D, Winqvist R, Pylkas K, Couch FJ,
Tischkowitz M.: PALB2, CHEK2 and ATM rare variants
and cancer risk: data from COGS, unpublished).
There is still very little data and no evidence sup-
porting an association between PALB2 mutations and
prostate cancer risk [13, 36–39] although several pedi-
grees have been presented and a possible trend toward
aggressive disease in carriers has been noted [39].
iCOGS measured PALB2 (c.1592delT, p.Leu531Cysfs
and c.3113G > A, p.Trp1038*) in 22,301 prostate can-
cer cases and 22,320 controls and found no evidence
for association with prostate cancer risk OR 2.06, 95 %
CI 0.59–7.11, p = 0.24 and OR 0.49, 95 % CI, 0.18–
1.36, p = 0.16 respectively.
The PALB2 interest group continues work to further
refine breast and other cancer risks for PALB2 mutation
carriers [19].PALB2 mutation carriers: clinical outcomes
As described above, recent work has increased the preci-
sion of breast cancer risk estimates for PALB2 mutation
carriers providing some new information with clinical
utility. However, prospective data related to the clinical
outcomes of PALB2 mutation carriers is lacking and very
little information (beyond mutation penetrance) is avail-
able to guide current clinical management for carriers
(affected and unaffected by breast cancer).
It has taken decades of research to provide the evidence
base for BRCA1 and BRCA2 mutation carriers to make
informed decision about the use of chemo-preventive
agents, the use of the bilateral salpingo-oophorectomy,
the use of mammography, magnetic resonance imaging
(MRI) and other screening modalities, risk reducing mast-
ectomy and targeted treatment regimes. Accumulating
this evidence was challenging due in part to the very low
frequency of women with BRCA1 and BRCA2 mutations,
the historically laborious and expensive process of testing
for mutations in these genes and the need to follow these
women prospectively.
However, in today’s context where PALB2 is being
included in gene panel tests that are being conducted
rapidly in large numbers at reduced costs and research
can be conducted in a coordinated fashion internationally
involving well established research resources (including re-
sources founded to assess these questions for BRCA1 and
BRCA2 mutation carriers) and in community-academic-
industry partnerships – there is promise that evidence can
be found for PALB2mutation carriers that will impact clin-
ical practice in the short term.
In the only report of its kind so far, Cybulski et al.,
identified 116 carriers of either 509_510delGA or
172_175delTTGT in 12,529 women diagnosed with in-
vasive breast cancer in Poland. Ten-year survival for
women with breast cancer and a PALB2 mutation was
48.0 % (95 % CI, 36.5 %–63.2 %), compared with 74.7 %
(95 % CI, 73.5 %–75.8 %) for non-carriers (hazard ratio
for death 2.27, 95 % CI, 1.64–3.15; p < 0.0001) [40].
Some other data indirectly supports a likely worse out-
come for PALB2 mutation carriers, including the propen-
sity in some population for PALB2 mutation-associated
breast cancers to be of higher grade, including triple nega-
tive. However, these reports are few and small in size, are
variable in findings and suggest PALB2 mutation-specific
tumour phenotypes [14, 15, 20, 41].
Further studies are required to test if women who
carry PALB2 mutations are at increased risk of death
from breast cancer compared to non-carriers. More in-
formation is needed to understand the options for pre-
vention and risk reduction. Intuitively, given the similar
biological role of the protein, it is likely that some of the
recommendations for BRCA1 and BRCA2 mutation car-
riers, including therapeutic regimes, may be relevant for
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resolve these questions.
To this end, a new academic-industry partnership
named PROMPT – Prospective Registry of Multiplex
Testing [42, 43], and many other large research initiatives
are underway to address these important questions for
carriers. PROMPT has scope beyond addressing these
questions for PALB2 alone and will support the rapid
translation of similar information for several new breast
cancer predisposition genes including ATM, CDH1,
CHEK2, RAD51C, RAD51D, STK11, TP53 in addition to
BRCA1 and BRCA2. PROMPT is an online research regis-
try for people who have undergone gene panel testing and
been found to have a genetic variation in one of the above
genes. PROMPT is one of several initiatives that create a
new paradigm for research study participation that dir-
ectly involves the most relevant community. PROMPT is
designed to involve those who want to share their genetic
results, learn more from sharing these results and engage
at a level of their choosing/comfort as a collaborator
alongside physicians and researchers to learn more about
how mutations in these genes (such as PALB2) may affect
their health and cancer risks.Classification of rare variants
In contrast to several other breast cancer predisposition
genes, there is no evidence that missense variants in
PALB2 (as a combined group) are associated with in-
creased risk for breast cancer [44, 45]. We and others
have reported that the breast cancer risk fraction con-
tributed by missense variants in BRCA1, BRCA2, ATM
and CHEK2 is as high, if not higher, than protein-
truncating variants in these genes [46–48]. However, in-
terpretation of the rare genetic variation observed in
PALB2 on a variant-by-variant basis, especially the rare
missense variants, remains challenging [44]. That is, on
a variant-by-variant basis it is difficult provide any infor-
mation that can be used to guide clinical management of
carriers of rare missense mutations.
In some practices, the previous approach of breast
cancer clinical genetics to generalize risk within groups
of similar mutations (e.g., protein truncating mutations
in BRCA1) has not been automatically applied in the
context of PALB2 due to i) a perception that the PALB2
risk estimates currently include data from a dispropor-
tionate number of the founder PALB2 mutations (and
thus may not represent the average risk associated with
all loss-of-function mutations) and ii) the more recent
characterisation of variants in BRCA1 (e.g., R1699Q
[49, 50]) and BRCA2 (e.g., K3326* [51, 52]) with more
moderate or low risk of breast cancer that is also a
plausible scenario for variants in other genes, including
PALB2.There is therefore a need to extend international ef-
forts that are currently trying to classify rare variants
identified in BRCA1 and BRCA2 for clinical use to in-
clude rare variants identified in PALB2 (and other genes)
to assist the clinical management of the individuals who
carry them. Several activities are well underway.
The most extensive and internationally set groups work-
ing in this area include The PALB2 Interest Group [6, 19]
and The Evidence-based Network for the Interpretation of
Germline Mutation Alleles (ENIGMA) [53–55] whose
members are providing a range of data to accumulate new
evidence on a variant-by-variant basis to be assessed in
multifactorial risk models. These groups are also providing
expert opinion to global databases and classification initia-
tives and working to communicate new information to
clinical genetics practices urgently in need of individual-
ized information.
The assessment and clinical classification of rare mis-
sense variants in PALB2 are likely to require incorporation
of many pieces of evidence to enable clinical utility. Some
of this evidence is likely to come from so-called functional
assays. Fortunately, several functional domains of PALB2
are recognized including a coiled-coil structure, an ETGE-
type KEAP1 binding motif, a chromatin-association motif
(ChAM) at the N-terminus and a WD repeat motif in the
C-terminus (reviewed elsewhere [10]). These domains,
coupled with PALB2’s role in DNA repair and Fanconi
anemia, are facilitating work that is pitched at assessing
the functional differences between wildtype PALB2 and
PALB2 carrying rare missense mutations in key functional
domains. Park et al., characterized effects of missense mu-
tations of the PALB2 WD40 domain and demonstrated
that PALB2 L939W (c.2816 T >G) and PALB2 L1143P
(c.3428 T >A) display a decreased capacity for DNA
double-strand break-induced homologous recombination
and an increased cellular sensitivity to ionizing radiation
[56]. This data offers much potentially useful information
for rare variant classification - yet key questions still need
to be answered. For instance, 1) how should these assays
be calibrated (i.e., how much change of function equates
to increased cancer risk)?; 2) is the magnitude of func-
tional change proportional to magnitude of cancer risk?;
3) how should these results be coded, weighted and incor-
porated into multifactorial risk models?
Calibrated assays for functional assessment of variants
in BRCA1 and BRCA2 have been developed and reported
[57, 58]. Recently, a publically available resource for func-
tional analysis of missense variants in BRCA1 (BRCA1
Circos) has been made available to facilitate meta-analysis
of functional data and improve classification of variants in
that gene [59]. It is anticipated that groups such as the
Functional Working Group of ENIGMA [60] will be able
to develop similar resources for PALB2 once assays are
further developed and data is available.
Southey et al. Hereditary Cancer in Clinical Practice  (2016) 14:9 Page 6 of 7Conclusions: towards precision medicine
There is much well founded optimism in the research
community that a number of large initiates (some de-
tailed here) will generate data quickly, on the necessary
scale and pooled to make definitive analyses related to
variant classification and clinical outcomes for PALB2
carriers a reality in the near future.
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